ASTRAZENECA PLC (AZN)
AstraZeneca plc (NASDAQ: AZN) is a global biopharmaceutical company headquartered in Cambridge, United Kingdom. It discovers, develops, and commercializes prescription medicines across oncology, cardiovascular, renal and metabolism, respiratory and immunology, and rare diseases. Its major medicines include Tagrisso, Imfinzi, Farxiga, Symbicort, and Ultomiris.
| Ticker | AZN |
|---|
| Company | ASTRAZENECA PLC |
|---|
| Exchange | NYSE |
|---|
| Headquarters | CAMBRIDGE |
|---|
Income statement — period ending 2025-12-31
| BasicEarningsLossPerShare | 7 USD/shares |
|---|
| CostOfSales | $10,633,000,000 |
|---|
| DilutedEarningsLossPerShare | 7 USD/shares |
|---|
| GrossProfit | $48,106,000,000 |
|---|
| ProfitLoss | $10,233,000,000 |
|---|
| ProfitLossAttributableToOwnersOfParent | $10,225,000,000 |
|---|
| ProfitLossFromOperatingActivities | $13,743,000,000 |
|---|
| ResearchAndDevelopmentExpense | $14,232,000,000 |
|---|
| Revenue | $58,739,000,000 |
|---|
| SellingGeneralAndAdministrativeExpense | $19,933,000,000 |
|---|
Sourced from SEC EDGAR/XBRL filings via StockSpectro.
View full interactive research on StockSpectro